|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-3-28
|
|
pubmed:abstractText |
It is important to establish pharmacokinetic or pharmacodynamic differences between novel insulin analogues and human insulin. This study examined the primary metabolic degradation products of insulin glargine (LANTUS) in humans.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0300-7995
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
34-40
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12661778-Adolescent,
pubmed-meshheading:12661778-Adult,
pubmed-meshheading:12661778-Biotransformation,
pubmed-meshheading:12661778-Blood Glucose,
pubmed-meshheading:12661778-Chromatography, High Pressure Liquid,
pubmed-meshheading:12661778-Humans,
pubmed-meshheading:12661778-Hypoglycemic Agents,
pubmed-meshheading:12661778-Injections, Subcutaneous,
pubmed-meshheading:12661778-Insulin,
pubmed-meshheading:12661778-Insulin, Long-Acting,
pubmed-meshheading:12661778-Male,
pubmed-meshheading:12661778-Middle Aged,
pubmed-meshheading:12661778-Radioimmunoassay,
pubmed-meshheading:12661778-Reference Values
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
|
|
pubmed:affiliation |
Aventis Pharma Deutschland GmbH, Frankfurt, Germany. GertUlrich.kuerzel@aventis.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't
|
